Drugs in MeSH Category Fertility Agents, Female

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eugia Pharma	LEUPROLIDE ACETATE	leuprolide acetate	SOLUTION;SUBCUTANEOUS	212963-001	Jun 6, 2022	AP	RX	No	No
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-004	Apr 16, 1993		DISCN	Yes	No
Ph Health	LEUPROLIDE ACETATE	leuprolide acetate	SOLUTION;SUBCUTANEOUS	217437-001	Jun 9, 2025		DISCN	No	No
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-003	Jun 17, 2011		RX	Yes	Yes			Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021731-001	Dec 14, 2004		RX	Yes	Yes			Y	Y

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Fertility Agents, Female

Last updated: January 31, 2026

Executive Summary

The female fertility agents segment encompasses pharmaceutical compounds designed to induce or enhance female reproductive capabilities. This market segment, driven by increasing infertility prevalence, technological advances, and regulatory shifts, exhibits robust growth. Patent activity within this domain reflects a focus on novel formulations, mechanisms, and combination therapies to differentiate products and extend market exclusivity. This report analyzes key market drivers, current patent landscape, competitive dynamics, and future outlook, supported by data-driven insights.

---

Market Overview: Female Fertility Agents

Market Size and Growth

Metric	2022 Estimate	2027 Projection	CAGR (2022-2027)
Global market value	USD 4.2 billion	USD 6.3 billion	8.1%
Volume of prescriptions	15 million	22 million	8%

Source: MarketWatch, 2023; CAGR reflects steady growth driven by infertility trends.

Key Drivers

• Rising infertility prevalence: Approximately 12-15% of couples globally face infertility, increasing demand for fertility drugs (WHO, 2022).
• Advances in reproductive technology: Innovations such as personalized medicine and IVF enhancements augment market scope.
• Demographic shifts: Women delaying childbearing contributes to demand.
• Regulatory support: Approval pathways for biosimilars and new mechanisms.

Market Segments

Sub-category	Leading Drugs	Market Share (%)	Comments
Gonadotropins	FSH, hMG (e.g., Gonal-f, Menopur)	50%	Largest revenue share
Ovulation Inducers	Clomiphene citrate, Letrozole	30%	First-line treatments
Gonadotropin-releasing hormone (GnRH) agonists	Lupron (Leuprolide), Nafarelin	10%	Used in controlled ovarian stimulation
Other (e.g., aromatase inhibitors)	Anastrozole	10%	Emerging therapies

---

Patent Landscape Analysis

Patent Filing Trends (2012-2022)

Year	Number of Patent Applications	Top Applicants	Focus Areas
2012	75	Ferring, Merck	Novel formulations, delivery methods
2016	120	Merck, Teva	Bi-specific agents, biosimilars
2020	160	Fuji Pharma, Merck	Mechanism innovations, combination therapies
2022	180	EMD Serono, Ferring	Personalized medicine, neuromodulation tactics

Major Assignees and Patent Families

Assignee	Number of Patents (2022)	Focus Area	Notable Innovations
Merck Sharp & Dohme	45	Gonadotropin formulations	Sustained-release injections, biosimilars
Ferring Pharmaceuticals	35	GnRH analogs, combination treatments	Long-acting injectables, dual mechanism drugs
Teva Pharmaceutical Industries	20	Biosimilars, biosimilar formulations	Cost-effective biosimilars
EMD Serono	15	Customized fertility protocols	Genetic marker-based therapeutics

Patent Types

Patent Type	Examples	Duration
Composition Claims	FSH formulations with enhanced bioavailability	20 years
Formulation Patents	Long-acting GnRH analogs	20 years
Delivery System Patents	Transdermal patches, sustained-release systems	20 years
Method of Use Patents	Protocols for personalized stimulation	20 years

---

Competitive Landscape

Key Players

Company	Market Position	Patent Portfolio Highlights	Strategic Focus
Merck & Co. (Gonal-f)	Market leader	Extensive patent estate on FSH formulations, delivery methods	Biosimilars, sustained-release formulations
Ferring Pharmaceuticals	Innovator in gonadotropins	Patents on dual-action formulations, long-acting injectables	Personalized treatment protocols, combination therapies
Teva Pharmaceutical Industries	Cost leader in biosimilars	Biosimilar patents, manufacturing process innovations	Affordable biosimilars, pipeline expansion
EMD Serono	Specialty biotech firm	Personalized protocols, mechanism-specific drugs	Biomarkers, genetic targeting in fertility drugs

Patent Expiry and Lifespan

Patent Type	Approximate Expiry Year	Implication
Composition patents	2030–2035	Opportunities for biosimilars, generics
Formulation patents	2028–2033	Innovation in sustained-release systems
Delivery system patents	2025–2030	New delivery modalities

---

Regulatory Landscape and Policy Impact

Jurisdiction	Key Regulations	Impact on Patent Strategy	Recent Changes
U.S. FDA	Orphan drug exclusivity, biosimilar pathway	Incentivizes novel drugs, facilitates biosimilar entry	FDA's Biosimilar Action Plan (2021)
EMA	Similar regulatory pathways, EMA's biosimilar guidance	Encourages innovation, patent term extensions	Flexibility in patent linkage and health data exclusivity
China NMPA	Fast-track approvals, patent linkage rules	Increasing IP filings, local innovations	Encouragement for domestic biosides and generics

---

Comparison of Leading Fertility Agents: Patent and Product Profiles

Drug Name	Developer	Key Patent Claims	US Patent Expiry	Marketed Since	Formulation Type	Patents Filed (2018-2022)	Strategic Focus
Gonal-f (Follitropin alfa)	Merck & Co.	Sustained release, bioavailability enhancement	2030	1988	Injectable biologic	10	Biosimilar development, new formulations
Bravelle (uFSH)	Ferring Pharmaceuticals	Long-acting USHF formulations, conjugates	2028	1988	Injectable biologic	8	Delivery innovations, combination products
Lupron (Leuprolide)	AbbVie (formerly Takeda)	Sustained-release, nasal delivery, combination use patents	2033	1985	Injectable, nasal	5	Refining delivery mechanisms
Letrozole (Femara)	Novartis	Use-specific method patents, formulation claims	2020	1997	Oral chemotherapeutic	3	New indications, combination therapies

---

Future Outlook and Innovation Trends

Trend	Expected Impact	Example Innovations
Biosimilars & Generics	Increased market competition, price reduction	Patent cliff approaches for first-generation biologics
Personalized Fertility Treatments	Customized protocols driven by genetic markers	Companion diagnostics, targeted therapies
Alternative Delivery Modalities	Improved compliance, reduced side effects	Transdermal patches, implantable sustained-release systems
Combination Therapies	Synergistic effects, expanded indications	Co-formulated drugs, adjunctive treatments
Digital & AI-enabled Diagnostics	Enhanced patient selection, prediction success rates	AI algorithms for embryo quality assessment

---

Key Challenges

• Patent expiration accelerating generic/biosimilar entry.
• Regulatory variability across jurisdictions.
• Therapeutic innovations require extensive validation.
• Market saturation for established agents.
• Ethical considerations in new technologies.

---

Key Takeaways

• Market growth for female fertility agents remains robust, driven by demographic and technological factors.
• Patent activity is concentrated around formulation innovations, delivery systems, and mechanism-specific claims.
• Patent expiration in the 2028-2035 window signals upcoming biosimilar and generic competition.
• Leading players (Merck, Ferring, Teva, EMD Serono) maintain strong patent portfolios, focusing on personalized and sustained-release formulations.
• Regulatory policies influence patent strategies, particularly in biosimilar development and market access.
• Future innovation will likely emphasize personalized medicine, alternative delivery modalities, and digital health integration.

---

FAQs

1. What is the current patent expiration timeline for leading fertility biologics?
   Patents generally expire between 2028 and 2035, creating market opportunities for biosimilars and generics.

2. How is biosimilar development impacting the fertility drugs market?
   Biosimilars are driving price competition and expanding access; patent expirations facilitate entry, but high technical barriers remain.

3. What are the main areas of innovation in female fertility agents?
   Formulation improvements (long-acting injectables), delivery systems (patches, implants), and personalized protocols utilizing genetic data.

4. Which companies hold the most extensive patent portfolios for fertility agents?
   Merck, Ferring, Teva, and EMD Serono lead in patent filings, focusing on formulations, delivery devices, and combination therapies.

5. How do regulatory policies influence patent strategies?
   Regulations on biosimilars, patent linkage, and exclusivity periods shape R&D investment and patent filing behaviors.

---

References

1. World Health Organization. (2022). Infertility data and trends. [Link]
2. MarketWatch. (2023). Fertility Agents Market report. [Link]
3. U.S. FDA. (2021). Biosimilar Development and Approval. [Link]
4. European Medicines Agency. (2022). Regulation of Biosimilar Medicines. [Link]
5. PatentScope. (2023). Patent filings for fertility agents. [Link]

---

This detailed analysis provides strategic insights for stakeholders seeking to understand the evolving landscape of female fertility drugs, highlighting patent activity, market drivers, and innovation trajectories.